Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 365-373

  Takahashi, Harumi ^a   Kashima, Toshitaka ^b   Nomoto, Shinichi ^c   Iwade, Kazunori ^d   Tainaka, Hitoshi ^e   Shimizu, Teppei ^a   Nomizo, Yuko ^a   Muramoto, Nagisa ^a   Kimura, Sosuke ^b   Echizen, Hirotoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^e Central Laboratory   (Japan)

Author keywords

Allelic variant; Cytochrome P4502C9 (S) warfarin clearance; Genotype

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; WARFARIN;

ADULT; AGED; ALLELE; ARTICLE; CATALYSIS; CHILD; CONTROLLED STUDY; CORRELATION FUNCTION; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; JAPAN; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYDROXYLATION; LEUCINE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POLYMORPHISM, GENETIC; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 7844247934     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00001     Document Type: Article

References (31)

1. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-58.
2. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15:424-430.
3. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7:203-210.
4. Giga-Hama Y, Tohda H, Okada H, Owada MK, Okayama H, Kumagai H. High-level expression of human lipocortin I in the fission yeast Schizosaccharomyces pombe using a novel expression vector. Biotechnology 1994; 12:400-404.
5. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
6. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267:83-90.
7. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
8. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants: an update. Clin Pharmacokinet 1996; 30:416-444.
9. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolubutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997; 7:105-113.
10. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993; 43:234-239.
11. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7:405-409.
12. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-292.
13. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I: evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
14. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16:348-354.
15. Phillips AH, Langdon RG. Hepatic triphosphopyridine nucleotide-cytochrome C reductase: isolation, characterization, and kinetic studies. J Biol Chem 1962; 237:2652-2660.
16. Porter RS, Sawyer WT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ. editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics Inc: 1992. pp. 1-46.
17. Rettie AE, Korzekwa KR, Kunze KL, Laurence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5:54-59.
18. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
19. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
20. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
21. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59:215.
22. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*5. Pharmacogenetics 1997; 7:361-367.
23. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
24. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
25. Takahashi H, Kashima T, Kimura S, Muramoto N, Nakahata H, Kubo S, et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B 1997; 701:71-80.
26. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese cardiac patients with different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63:519-528.
27. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289:533-538.
28. Wagner JG, Ayres JW. Bioavailability assessment: methods to estimate total area (AUC 0-8) and total amount excreted (Ae8) and importance of blood and urine sampling scheme with application to digoxin. J Pharmacokinet Biopharm 1977; 5:533-557.
29. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5:37-42.
30. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18:377-390.
31. 5 interactions. Arch Biochem Biophys 1997; 342:329-337.